Aspirin use and risk of age-related macular degeneration: a meta-analysis.

BACKGROUND: Age-related macular degeneration (AMD) is the main cause of blindness and the curative options are limited. The objective of this meta-analysis was to determine the association between aspirin use and risk of AMD. METHODS: A comprehensive literature search was performed in PubMed, Embase...

Full description

Bibliographic Details
Main Authors: Wei Zhu, Yan Wu, Ding Xu, Yan-Hong Li, Ba Jun, Xiao-Long Zhang, Fang Wang, Jing Yu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3597550?pdf=render
id doaj-dcca60a031fa4ba2baf8f09c120f8fe5
record_format Article
spelling doaj-dcca60a031fa4ba2baf8f09c120f8fe52020-11-25T02:32:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0183e5882110.1371/journal.pone.0058821Aspirin use and risk of age-related macular degeneration: a meta-analysis.Wei ZhuYan WuDing XuYan-Hong LiBa JunXiao-Long ZhangFang WangJing YuBACKGROUND: Age-related macular degeneration (AMD) is the main cause of blindness and the curative options are limited. The objective of this meta-analysis was to determine the association between aspirin use and risk of AMD. METHODS: A comprehensive literature search was performed in PubMed, Embase, Web of Science, and reference lists. A meta-analysis was performed by STATA software. RESULTS: Ten studies involving 171,729 individuals examining the association between aspirin use and risk of AMD were included. Among the included studies, 2 were randomized-controlled trials (RCTs), 4 were case-control studies and 4 were cohort studies. The relative risks (RRs) were pooled using a random-effects model. Relative risks with 95% confidence intervals (CIs) of aspirin use as a risk for AMD. The pooled RR of 10 included studies between the use of aspirin and risk of AMD was 1.09 (95% CI, 0.96-1.24). The same result was detected in early and late stage AMD subgroup analysis. In the subgroup analyses, the pooled RR of RCTs, case-control studies and cohort studies were 0.81 (95% CI, 0.64-1.02), 1.02 (95% CI, 0.92-1.14) and 1.08 (95% CI, 0.91-1.28), respectively. CONCLUSIONS: The use of aspirin was not associated with the risk of AMD.http://europepmc.org/articles/PMC3597550?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Wei Zhu
Yan Wu
Ding Xu
Yan-Hong Li
Ba Jun
Xiao-Long Zhang
Fang Wang
Jing Yu
spellingShingle Wei Zhu
Yan Wu
Ding Xu
Yan-Hong Li
Ba Jun
Xiao-Long Zhang
Fang Wang
Jing Yu
Aspirin use and risk of age-related macular degeneration: a meta-analysis.
PLoS ONE
author_facet Wei Zhu
Yan Wu
Ding Xu
Yan-Hong Li
Ba Jun
Xiao-Long Zhang
Fang Wang
Jing Yu
author_sort Wei Zhu
title Aspirin use and risk of age-related macular degeneration: a meta-analysis.
title_short Aspirin use and risk of age-related macular degeneration: a meta-analysis.
title_full Aspirin use and risk of age-related macular degeneration: a meta-analysis.
title_fullStr Aspirin use and risk of age-related macular degeneration: a meta-analysis.
title_full_unstemmed Aspirin use and risk of age-related macular degeneration: a meta-analysis.
title_sort aspirin use and risk of age-related macular degeneration: a meta-analysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description BACKGROUND: Age-related macular degeneration (AMD) is the main cause of blindness and the curative options are limited. The objective of this meta-analysis was to determine the association between aspirin use and risk of AMD. METHODS: A comprehensive literature search was performed in PubMed, Embase, Web of Science, and reference lists. A meta-analysis was performed by STATA software. RESULTS: Ten studies involving 171,729 individuals examining the association between aspirin use and risk of AMD were included. Among the included studies, 2 were randomized-controlled trials (RCTs), 4 were case-control studies and 4 were cohort studies. The relative risks (RRs) were pooled using a random-effects model. Relative risks with 95% confidence intervals (CIs) of aspirin use as a risk for AMD. The pooled RR of 10 included studies between the use of aspirin and risk of AMD was 1.09 (95% CI, 0.96-1.24). The same result was detected in early and late stage AMD subgroup analysis. In the subgroup analyses, the pooled RR of RCTs, case-control studies and cohort studies were 0.81 (95% CI, 0.64-1.02), 1.02 (95% CI, 0.92-1.14) and 1.08 (95% CI, 0.91-1.28), respectively. CONCLUSIONS: The use of aspirin was not associated with the risk of AMD.
url http://europepmc.org/articles/PMC3597550?pdf=render
work_keys_str_mv AT weizhu aspirinuseandriskofagerelatedmaculardegenerationametaanalysis
AT yanwu aspirinuseandriskofagerelatedmaculardegenerationametaanalysis
AT dingxu aspirinuseandriskofagerelatedmaculardegenerationametaanalysis
AT yanhongli aspirinuseandriskofagerelatedmaculardegenerationametaanalysis
AT bajun aspirinuseandriskofagerelatedmaculardegenerationametaanalysis
AT xiaolongzhang aspirinuseandriskofagerelatedmaculardegenerationametaanalysis
AT fangwang aspirinuseandriskofagerelatedmaculardegenerationametaanalysis
AT jingyu aspirinuseandriskofagerelatedmaculardegenerationametaanalysis
_version_ 1724818964740046848